Device-Based Therapy for Hypertension: New Frontiers in Patient Care

The Case for Device-Based Therapy for Hypertension“If you think about hypertension, it’s a global healthcare crisis,” said Eso. “Half of this auditorium probably has it. It’s bigger than diabetes, bigger than many other diseases from a cardiovascular perspective.”Eso traced Medtronic’s entry into hypertension therapeutics back to its 2009 investment in Ardian, the pioneer behind renal denervation devices. At the time, hypertension management was still viewed almost exclusively through a pharmaceutical lens. Devices weren’t yet considered part of the solution. However, early clinical learnings revealed significant gaps that medication alone couldn’t fill—particularly in adherence.“75% of people with hypertension are uncontrolled even when they’re on meds,” noted Eso. “There are side effects. There are compliance issues. Taking three to five medications every day for the rest of your life—it’s tough. Device-based therapies offer an alternative that doesn’t rely on daily compliance.”Hochman agreed, framing hypertension as “the trunk of the tree” that leads to heart attack, stroke, heart failure, and kidney disease. Addressing it effectively, he emphasized, means addressing the root cause of downstream morbidity and mortality.This blog is originally published here: https://www.lsiusasummit.com/news/device-basedtherapy-for-hypertension-new-frontiers-in-patient-care